A Study of AZD1222, a Vaccine for the Prevention of COVID-19 in Immunocompromised Adults

Trial Identifier: D8111C00010
Sponsor: AstraZeneca
NCTID:: NCT05057897
Start Date: January 2022
Primary Completion Date: April 2023
Study Completion Date: April 2023

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

Language Description
English Version
Russian (Ukraine) Translation
Thai Translation
Ukrainian Translation

Trial Locations

Country Location
CO Barranquilla, CO, 80001
CO Bucaramanga, CO
CO Floridablanca, CO, 680006
EG Cairo, EG, 11796
EG Cairo, EG, 11566
EG New Cairo, EG, 11566
IN Ajmer, IN, 305001
IN Bangalore, IN, 560068
IN Bhubaneswar, IN, 751003
IN Faridabad, IN, 121012
IN Kolkata, IN, 700054
IN Nagpur, IN, 440008
IN New Delhi, IN, 110060
IN Pune, IN, 411 018
IN Pune, IN, 411001
IN Surat, IN, 395009
TH Bangkok, TH, 10700
TH Bangkok, TH, 10330
TH Khon Kaen, TH, 40002
TH Muang, TH, 50200
TR Diyarbakir, TR, 21280
TR Kayseri, TR, 38080
UA Ivano-Frankivsk, UA, 76007
UA Kharkiv, UA, 61052
UA Kyiv, UA, 3126
UA m. Lviv, UA, 79011
VN Hanoi, VN, 100000